Anti-deamidated gliadin peptides (anti-DGP) IgG antibodies are autoantibodies directed against gliadin peptides that have undergone deamidation, a process catalyzed by tissue transglutaminase. Deamidation enhances the immunogenicity of gliadin, a component of gluten, triggering a stronger immune response in individuals with celiac disease. Anti-DGP IgG has emerged as a valuable serologic marker, particularly in cases where traditional markers like anti-tTG IgA may be inconclusive.
In clinical settings, anti-DGP IgG is especially useful for diagnosing celiac disease in patients with selective IgA deficiency or in young children, where IgA responses may be underdeveloped. It can serve as an alternative or complementary marker when anti-tTG IgA is negative but suspicion of celiac disease remains high. When combined with other serologic tests, it enhances diagnostic accuracy and may reduce the need for intestinal biopsy in certain cases. In research, anti-DGP IgG helps to further understand gluten-related immune responses, monitor dietary adherence, and explore non-classical or extra-intestinal manifestations of gluten sensitivity. It also plays a role in developing and validating novel diagnostic strategies for celiac disease and related gluten-mediated disorders.
This product is manufactured in Italy by Diametra.